ML models, such as the one that we developed, can be used to calculate the probability of wild-type ATTR-CM in HF patients and elevate the index of suspicion, after which further confirmatory testing can be done, thereby enhancing diagnosis and clinical recognition of wild-type ATTR-CM, which is increasingly important given the high morbidity and mortality of wild-type ATTR-CM and the availability of tafamidis, a disease-modifying therapy. This evidence concerns the gene TTR and hydrops fetalis.